<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04901962</url>
  </required_header>
  <id_info>
    <org_study_id>C2612</org_study_id>
    <nct_id>NCT04901962</nct_id>
  </id_info>
  <brief_title>Study to Evaluate Made-to-measure Compression Garments</brief_title>
  <official_title>Prospective Multicentre Study to Evaluate the Clinical Performance and Safety of Innovative, Made-to-measure Compression Garments in Daily Routine</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>BSN Medical GmbH</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>BSN Medical GmbH</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective is to collect real-life data to evaluate the clinical performance and&#xD;
      safety of innovative, made-to-measure, flat knitted, CE-marked compression garments for&#xD;
      daytime treatment of leg or arm lymphedema (ISL stage I-II) in daily routine by analysing&#xD;
      performance parameters and safety parameters reported during the investigation.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The secondary objective is to evaluate (1) patients' quality of life QoL before and after&#xD;
      having tested JOBST Confidence and (2) patient satisfaction focussing on patient reported&#xD;
      outcomes of previously worn garments and JOBST® Confidence by analysing patient&#xD;
      questionnaires parameters completed at the beginning and in the end of the wearing period.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 21, 2021</start_date>
  <completion_date type="Anticipated">December 30, 2021</completion_date>
  <primary_completion_date type="Anticipated">December 30, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Clinical performance: circumference of the edema</measure>
    <time_frame>change from baseline after a treatment duration of 7, 14, and 21 days</time_frame>
    <description>Circumference measurements at selected points of the limb (taken manually using measuring tape) [cm]</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Clinical performance: edema status</measure>
    <time_frame>change from baseline after a treatment duration of 7, 14, and 21 days</time_frame>
    <description>Evaluation of edema (visual inspection and palpitation) according to standardized criteria</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Quality of Life assessed by patient questionnaire</measure>
    <time_frame>assessed before treatment and after 21 days of treatments with JC</time_frame>
    <description>extend of restrictions regarding work due to the lymphoedema (indicated on a 5-point scale)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of Life assessed by patient questionnaire</measure>
    <time_frame>assessed before treatment and after 21 days of treatments with JC</time_frame>
    <description>extend of restrictions regarding leisure time due to the lymphoedema (indicated on a 5-point scale)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of Life assessed by patient questionnaire</measure>
    <time_frame>assessed before treatment and after 21 days of treatments with JC</time_frame>
    <description>extend of restrictions regarding psychological well-being due to the lymphoedema (indicated on a 5-point scale)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient satisfaction assessed by patient questionnaire</measure>
    <time_frame>assessed before treatment and after 21 days of treatments with JC</time_frame>
    <description>Comparison of patient reported outcomes regarding previously worn compressions garments and JC</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">110</enrollment>
  <condition>Lymphedema</condition>
  <arm_group>
    <arm_group_label>JOBST® Confidence compression garments</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The CE-marked class I medical devices JOBST® Confidence compression garments for lower and upper extremities will be tested under routine conditions according to their selected intended use. Subjects will be treated with either thigh-high compression stockings (AG) or arm compression garments without hand part (CG1), depending on their indication.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>JOBST® Confidence compression garments</intervention_name>
    <description>JOBST® Confidence (JC) compression garments will be used for daytime treatment of leg or arm lymphedema. JC compression garments exert a specific therapeutic external, physical compression level and are therefore intended to use for the management of edema. JC comprise non-invasive medical devices with no direct contact with injured skin or mucous membranes and are intended for use on intact skin only.</description>
    <arm_group_label>JOBST® Confidence compression garments</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Signed Informed Consent Form&#xD;
&#xD;
          2. Men, women or diverse aged 18 years or up to 70 years with full legal competence&#xD;
&#xD;
          3. Patient is mentally and physically able to participate in the study&#xD;
&#xD;
          4. Capability to understand the subject information and to provide conscious informed&#xD;
             consent&#xD;
&#xD;
          5. Capability and willingness to follow protocol requirements&#xD;
&#xD;
          6. All female or diverse subjects of childbearing potential must agree to use a reliable&#xD;
             method of contraception with a Pearl-Index of less than 1% per year when used&#xD;
             consistently and correctly* (*such as hormone implants,injectables, combined oral&#xD;
             contraceptives (combined gestagen-estrogen pills), some intra uterine devices (IUDs),&#xD;
             surgically sterility (hysterectomy or tubal ligation), sexual abstinence or&#xD;
             vasectomized partner for at least 4 weeks)&#xD;
&#xD;
          7. Mild to moderate lymphedema of the lower and/or upper extremities (ISL stage I or II)&#xD;
&#xD;
          8. Indication and possibility of treatment with a flat-knitted compression garment during&#xD;
             the day&#xD;
&#xD;
          9. Patients who are familiar with wearing compression garments&#xD;
&#xD;
         10. Indicated Complete Decongestive Therapy Phase II (Maintenance phase)&#xD;
&#xD;
         11. Willingness to wear the study product at least 5 days a week for at least 6 hours a&#xD;
             day&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Pregnant or lactating women or diverse subjects&#xD;
&#xD;
          2. Alcohol abuse (mentioned by the patient and/or suspected by the investigator)&#xD;
&#xD;
          3. Drug abuse (mentioned by the patient and/or suspected by the investigator)&#xD;
&#xD;
          4. Patients who need a different compression class (higher or lower than CCL 2)&#xD;
&#xD;
          5. Pronounced skin folds&#xD;
&#xD;
          6. Pronounced shape distortions&#xD;
&#xD;
          7. cG (lymphatic measure of the thigh) &gt;90 cm for AG stocking&#xD;
&#xD;
          8. Indicated Complete Decongestive Therapy Phase I&#xD;
&#xD;
          9. Known allergy or intolerance to one or more components of the product&#xD;
&#xD;
         10. Advanced arterial insufficiency including ischemia&#xD;
&#xD;
         11. Uncontrolled congestive heart failure&#xD;
&#xD;
         12. Untreated septic phlebitis&#xD;
&#xD;
         13. Phlegmasia coerulea dolens&#xD;
&#xD;
         14. Immobility (confinement to bed).&#xD;
&#xD;
         15. Conditions in which increased venous and lymphatic return is not desired.&#xD;
&#xD;
         16. Weeping dermatosis&#xD;
&#xD;
         17. Cutaneous infections&#xD;
&#xD;
         18. Severely compromised skin sensibility and impaired sensitivity of the limb&#xD;
&#xD;
         19. Advanced peripheral neuropathy&#xD;
&#xD;
         20. Rheumatoid arthritis&#xD;
&#xD;
         21. Complex regional pain syndrome (CRPS, M. Sudeck)&#xD;
&#xD;
         22. Malignant lymphedema&#xD;
&#xD;
         23. Gangrene&#xD;
&#xD;
         24. Sponsors or manufacturers staff&#xD;
&#xD;
         25. Open wounds in the test area&#xD;
&#xD;
         26. Diuretics, except low doses for treatment of hypertension (≤ 12.5 mg&#xD;
             Hydrochlorothiazide)&#xD;
&#xD;
         27. Nephrotic syndrome&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Tobias Hirsch, Dr. med.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Praxis für Innere Medizin und Gefäßkrankheiten</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Swaantje Hoffstedt</last_name>
    <phone>+49 174</phone>
    <phone_ext>3162215</phone_ext>
    <email>swaantje.hoffstedt@essity.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Gefäßkrankheiten Rhein-Ruhr</name>
      <address>
        <city>Essen</city>
        <state>Nordrhein-Westfalen</state>
        <zip>45131</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Helene Arns, Dr. med.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Praxis für Innere Medizin und Gefäßkrankheiten</name>
      <address>
        <city>Halle (Saale)</city>
        <state>Sachsen-Anhalt</state>
        <zip>06108</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tobias Hirsch, Dr. med.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Dr. med. Jörg Schleinitz Facharzt für Allgemeinmedizin</name>
      <address>
        <city>Lützen</city>
        <state>Sachsen-Anhalt</state>
        <zip>06686</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jörg Schleinitz, Dr. med.</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>May 17, 2021</study_first_submitted>
  <study_first_submitted_qc>May 20, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">May 26, 2021</study_first_posted>
  <last_update_submitted>October 11, 2021</last_update_submitted>
  <last_update_submitted_qc>October 11, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 12, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphedema</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

